公开(公告)号：US07087241B2

公开(公告)日：2006-08-08

申请号：US11246558

申请日：2005-10-07

Applicant: Steven W. Sanders ,  Charles D. Ebert

Inventor： Steven W. Sanders ,  Charles D. Ebert

IPC: A61F13/00 ,  A61F13/02 ,  A61L15/16

CPC classification number: A61K9/0024 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/1647 ,  A61K9/7061 ,  A61K31/216 ,  A61K47/10 ,  A61K47/14 ,  A61K47/38 ,  A61K2300/00

Abstract: The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.

公开(公告)号：US07081252B2

公开(公告)日：2006-07-25

申请号：US10731824

申请日：2003-12-08

Applicant: Steven W. Sanders ,  Charles D. Ebert

Inventor： Steven W. Sanders ,  Charles D. Ebert

IPC: A61F13/00

CPC classification number: A61K9/0024 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/1647 ,  A61K9/7061 ,  A61K31/216 ,  A61K47/10 ,  A61K47/14 ,  A61K47/38 ,  A61K2300/00

Abstract: The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.

公开(公告)号：US07081249B2

公开(公告)日：2006-07-25

申请号：US10731039

申请日：2003-12-08

Applicant: Steven W. Sanders ,  Charles D. Ebert

Inventor： Steven W. Sanders ,  Charles D. Ebert

IPC: A61F13/00

CPC classification number: A61K9/0024 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/1647 ,  A61K9/7061 ,  A61K31/216 ,  A61K47/10 ,  A61K47/14 ,  A61K47/38 ,  A61K2300/00

Abstract: The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.

公开(公告)号：US06743441B2

公开(公告)日：2004-06-01

申请号：US10098752

申请日：2002-03-15

Applicant: Steven W. Sanders ,  Charles D. Ebert

Inventor： Steven W. Sanders ,  Charles D. Ebert

IPC: A61F1302

CPC classification number: A61K9/0024 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/1647 ,  A61K9/7061 ,  A61K31/216 ,  A61K47/10 ,  A61K47/14 ,  A61K47/38 ,  A61K2300/00

Abstract: The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.

公开(公告)号：US5766620A

公开(公告)日：1998-06-16

申请号：US553807

申请日：1995-10-23

Applicant: Sonia J. Heiber ,  Charles D. Ebert ,  Mark K. Gutniak

Inventor： Sonia J. Heiber ,  Charles D. Ebert ,  Mark K. Gutniak

IPC: A61K9/70 ,  A61K9/00 ,  A61K38/04 ,  A61K38/26 ,  A61L15/00 ,  A61F9/02 ,  A01N25/34 ,  A61K47/30 ,  A61K47/32

CPC classification number: A61K9/006 ,  A61K38/26

Abstract: Drug delivery systems and methods for administering a glucagon-like insulinotropic peptide to the buccal mucosa for transmucosal drug delivery are described. The drug delivery systems comprise a drug composition containing an effective amount of the glucagon-like insulinotropic peptide and an effective amount of a permeation enhancer for enhancing permeation of glucagon-like insulinotropic peptide through the buccal mucosa and means for maintaining the drug composition in a drug transferring relationship with with buccal mucosa. These systems can be in free form, such as creams, gels, and ointments, or can comprise a device of determined physical form, such as tablets, patches, and troches. A preferred glucagon-like insulinotropic peptide is GLP-1(7-36)amide.

Abstract translation: 描述了用于向口腔粘膜施用胰高血糖素样促胰岛素肽用于经粘膜药物递送的药物递送系统和方法。 药物递送系统包含含有有效量的胰高血糖素样促胰岛素肽的药物组合物和有效量的用于增强胰高血糖素样促胰岛素肽通过颊粘膜的渗透的渗透促进剂和用于将药物组合物保持在药物中的方法 转移与颊粘膜的关系。 这些系统可以是游离形式，例如乳膏，凝胶和软膏，或者可以包括具有确定的物理形式的装置，例如片剂，补片和锭剂。 优选的胰高血糖素样促胰岛素肽是GLP-1（7-36）酰胺。

公开(公告)号：US5346701A

公开(公告)日：1994-09-13

申请号：US27508

申请日：1993-02-22

Applicant: Sonia J. Heiber ,  Charles D. Ebert ,  Sirish C. Dave

Inventor： Sonia J. Heiber ,  Charles D. Ebert ,  Sirish C. Dave

IPC: A61K9/70 ,  A61K9/00 ,  A61K47/28 ,  A61F13/02

CPC classification number: A61K9/006 ,  Y10S514/953

Abstract: A method and system for mucosally administering a macromolecular drug to mucosa of the oral cavity is shown. The system comprises an inner drug/enhancer/polymer layer having one surface adapted to contact and adhere to the mucosal tissue of the oral cavity and an opposing surface in contact with and adhering to an overlying inert layer. The inner layer contains from about two to sixty percent by weight of a bile salt enhancer, five to sixty five percent by weight of a hydrophilic polymer which is water soluble or swellable and an effective amount of a macromolecular drug having a molecular weight of at least 500 daltons. Polysaccharides, polypeptides and proteins are preferred forms of macromolecular drugs. The bile salt enhancer facilitates the delivery of macromolecules such as low molecular weight heparin and calcitonin. The polymer serves as a plasticizer to prevent the crystallization and/or aggregation of such macromolecular drugs. Hydroxypropyl cellulose is a particularly suitable polymer.

Abstract translation: 显示了将大分子药物粘贴到口腔粘膜的方法和系统。 该系统包括内部药物/增强剂/聚合物层，其具有适于接触并粘附到口腔的粘膜组织的一个表面和与上覆惰性层接触并粘附到上覆惰性层的相对表面。 内层含有约百分之二至百分之六十重量百分比的胆汁盐增强剂，五至六十五重量％的亲水性聚合物，其是水溶性或可膨胀的，有效量的分子量至少为 500道尔顿 多糖，多肽和蛋白质是大分子药物的优选形式。 胆盐增强剂促进大分子如​​低分子量肝素和降钙素的递送。 聚合物用作增塑剂以防止这种大分子药物的结晶和/或聚集。 羟丙基纤维素是特别合适的聚合物。

公开(公告)号：US5202125A

公开(公告)日：1993-04-13

申请号：US625906

申请日：1990-12-10

Applicant: Charles D. Ebert ,  Dinesh Patel ,  Sonja Heiber

Inventor： Charles D. Ebert ,  Dinesh Patel ,  Sonja Heiber

IPC: A61K47/08 ,  A61K9/00 ,  A61K9/70 ,  A61K47/26

CPC classification number: A61K9/703 ,  A61K47/26 ,  A61K9/0014 ,  A61K9/7061 ,  Y10S514/946 ,  Y10S514/947

Abstract: Transdermal delivery systems for delivery of nitroglycerin are disclosed which deliver the drug at enhanced transdermal fluxes. The systems include, in addition to nitroglycerin, a permeation enhancer which is either a sorbitan ester, a C.sub.8 -C.sub.22 aliphatic alcohol, or a mixture thereof. Methods for administering nitroglycerin using such permeation enhancers are also disclosed.

Abstract translation: 公开了用于递送硝酸甘油的透皮递送系统，其以增强的经皮通量递送药物。 该系统除了硝酸甘油之外还包括渗透促进剂，其是脱水山梨糖醇酯，C 8 -C 22脂族醇或其混合物。 还公开了使用这种渗透促进剂来施用硝酸甘油的方法。

公开(公告)号：US5152997A

公开(公告)日：1992-10-06

申请号：US652127

申请日：1991-02-07

Applicant: Charles D. Ebert ,  Dinesh Patel ,  Werner Heiber

Inventor： Charles D. Ebert ,  Dinesh Patel ,  Werner Heiber

IPC: A61K9/06 ,  A61K9/70 ,  A61M37/00

CPC classification number: A61K9/7084

Abstract: Testosterone is administered transdermally through nonscrotal skin in a manner that mimics in amount and profile the natural production of testosterone in young adult healthy males. The testosterone is administered to the skin from a matrix which contains testosterone at subsaturation concentration and a permeation enhancer.

Abstract translation: 睾丸激素通过非皮肤皮肤经皮穿透，其模拟量和形状在年轻成年健康男性中睾酮的天然产生。 将睾丸激素从含有不饱和浓度的睾酮的基质和渗透促进剂施用于皮肤。

公开(公告)号：US5139023A

公开(公告)日：1992-08-18

申请号：US360876

申请日：1989-06-02

Applicant: Theodore H. Stanley ,  Charles D. Ebert ,  William I. Higuchi ,  Jie Zhang

Inventor： Theodore H. Stanley ,  Charles D. Ebert ,  William I. Higuchi ,  Jie Zhang

IPC: A61B5/00

CPC classification number: A61B5/14532 ,  Y10S514/975

Abstract: The present invention is directed to novel methods and apparatus for noninvasive blood glucose monitoring. Blood glucose is monitored noninvasively by correlation with amount of glucose which permeates an epithelial membrane, such as skin or a mucosal membrane, into a glucose receiving medium over a specified time period. The glucose receiving medium preferably includes a glucose permeation enhancer capable of increasing the glucose permeability across the epithelial membrane. The glucose receiving medium is positioned against the epithelial membrane so that the permeation enhancer alters the permeability of the membrane. After sufficient time delay, the glucose receiving medium is removed and analyzed for the presence of glucose using conventional analytical techniques.The apparatus within the scope of the present invention includes means for supporting the glucose receiving medium. Such means for supporting the glucose receiving medium may include a housing defining a receiving chamber therein which holds the glucose receiving medium and an opening to the receiving chamber. The means for supporting the glucose receiving medium may also include a hydrogel. The apparatus also preferably includes means for temporarily positioning the glucose receiving medium against the epithelial membrane.

Abstract translation: 本发明涉及用于无创血糖监测的新颖方法和装置。 通过与在特定时间段内渗透到葡萄糖接收介质中的上皮膜（例如皮肤或粘膜）的葡萄糖量的相关性，非侵入性地监测血糖。 葡萄糖接收培养基优选包括能够增加穿过上皮膜的葡萄糖渗透性的葡萄糖渗透增强剂。 葡萄糖接收介质抵靠上皮膜定位，使得渗透增强剂改变膜的渗透性。 在足够的时间延迟之后，使用常规分析技术去除葡萄糖接收培养基并分析葡萄糖的存在。 本发明范围内的装置包括用于支撑葡萄糖接收介质的装置。 用于支撑葡萄糖接收介质的这种装置可以包括限定其中容纳室的壳体，其保持葡萄糖接收介质和到接收室的开口。 支持葡萄糖接收介质的方法还可以包括水凝胶。 该装置还优选地包括用于将葡萄糖接收介质临时定位在上皮膜上的装置。